Literature DB >> 22023212

Natural killer cells preferentially target cancer stem cells; role of monocytes in protection against NK cell mediated lysis of cancer stem cells.

Anahid Jewett1, Han-Ching Tseng, Aida Arasteh, Saba Saadat, Russell E Christensen, Nicholas A Cacalano.   

Abstract

Mounting effective anti-tumor immune responses by cytotoxic effectors is important for the clearance of tumors. However, accumulated evidence suggests that the cytotoxic function of immune effectors is largely suppressed in the tumor microenvironment by a number of distinct effectors and their secreted factors. The aims of this review are to provide a rationale and potential mechanism for immunosuppression in cancer, and to demonstrate the significance of such immunosuppression in cellular differentiation and tissue regeneration in pathological conditions, and progression of cancer. We have recently shown that increased NK cell function was seen when they were cultured with primary oral squamous carcinoma stem cells (OSCSCs) as compared to their more differentiated oral squamous carcinoma cells (OSCCs). In addition, human embryonic stem cells (hESCs), Mesenchymal Stem Cells (hMSCs), dental pulp stem cells (hDPSCs) and induced pluripotent stem cells (hiPSCs) were significantly more susceptible to NK cell mediated cytotoxicity than their differentiated counterparts or parental cells from which they were derived. We have also reported that inhibition of differentiation or reversion of cells to a less-differentiated phenotype by blocking NFκB or targeted knock down of COX2 augmented NK cell function significantly. Total population of monocytes and those depleted of CD16(+) subsets were able to substantially prevent NK cell mediated lysis of OSCSCs, MSCs and DPSCs. Taken together, our results suggest that stem cells are significant targets of the NK cell cytotoxicity. The concept of split anergy in NK cells and its contribution to tissue repair and regeneration and in tumor resistance and progression will be discussed in this review. Therefore, patients with cancer may benefit from repeated allogeneic NK cell transplantation at the site of the tumor for specific elimination of cancer stem cells.

Entities:  

Mesh:

Year:  2012        PMID: 22023212     DOI: 10.2174/156720112798375989

Source DB:  PubMed          Journal:  Curr Drug Deliv        ISSN: 1567-2018            Impact factor:   2.565


  32 in total

1.  Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-γ after differentiation of glioblastoma by human natural killer cells.

Authors:  Anna K Kozlowska; Han-Ching Tseng; Kawaljit Kaur; Paytsar Topchyan; Akihito Inagaki; Vickie T Bui; Noriyuki Kasahara; Nicholas Cacalano; Anahid Jewett
Journal:  Cancer Immunol Immunother       Date:  2016-07-20       Impact factor: 6.968

2.  The stem cell markers Oct4A, Nanog and c-Myc are expressed in ascites cells and tumor tissue of ovarian cancer patients.

Authors:  Jiabo Di; Tjitske Duiveman-de Boer; Petra L M Zusterzeel; Carl G Figdor; Leon F A G Massuger; Ruurd Torensma
Journal:  Cell Oncol (Dordr)       Date:  2013-08-09       Impact factor: 6.730

Review 3.  The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications.

Authors:  Panagiota Economopoulou; Christos Perisanidis; Evaggelos I Giotakis; Amanda Psyrri
Journal:  Ann Transl Med       Date:  2016-05

4.  STAT1-S727 - the license to kill.

Authors:  Eva M Putz; Dagmar Gotthardt; Veronika Sexl
Journal:  Oncoimmunology       Date:  2014-12-13       Impact factor: 8.110

Review 5.  Strategies for isolating and enriching cancer stem cells: well begun is half done.

Authors:  Jiang-Jie Duan; Wen Qiu; Sen-Lin Xu; Bin Wang; Xian-Zong Ye; Yi-Fang Ping; Xia Zhang; Xiu-Wu Bian; Shi-Cang Yu
Journal:  Stem Cells Dev       Date:  2013-05-09       Impact factor: 3.272

6.  Malignant Pleural Effusion and ascites Induce Epithelial-Mesenchymal Transition and Cancer Stem-like Cell Properties via the Vascular Endothelial Growth Factor (VEGF)/Phosphatidylinositol 3-Kinase (PI3K)/Akt/Mechanistic Target of Rapamycin (mTOR) Pathway.

Authors:  Tao Yin; Guoping Wang; Sisi He; Guobo Shen; Chao Su; Yan Zhang; Xiawei Wei; Tinghong Ye; Ling Li; Shengyong Yang; Dan Li; Fuchun Guo; Zeming Mo; Yang Wan; Ping Ai; Xiaojuan Zhou; Yantong Liu; Yongsheng Wang; Yuquan Wei
Journal:  J Biol Chem       Date:  2016-10-18       Impact factor: 5.157

Review 7.  Targeting Head and Neck Cancer Stem Cells: Current Advances and Future Challenges.

Authors:  A C Birkeland; J H Owen; M E Prince
Journal:  J Dent Res       Date:  2015-08-25       Impact factor: 6.116

Review 8.  Advantages and clinical applications of natural killer cells in cancer immunotherapy.

Authors:  Erik Ames; William J Murphy
Journal:  Cancer Immunol Immunother       Date:  2013-08-30       Impact factor: 6.968

9.  Activated human primary NK cells efficiently kill colorectal cancer cells in 3D spheroid cultures irrespectively of the level of PD-L1 expression.

Authors:  Pilar M Lanuza; Alan Vigueras; Sara Olivan; Anne C Prats; Santiago Costas; Guillermo Llamazares; Diego Sanchez-Martinez; José María Ayuso; Luis Fernandez; Ignacio Ochoa; Julián Pardo
Journal:  Oncoimmunology       Date:  2018-02-12       Impact factor: 8.110

10.  Tumor-infiltrating immune cells promoting tumor invasion and metastasis: existing theories.

Authors:  Yan-Gao Man; Alexander Stojadinovic; Jeffrey Mason; Itzhak Avital; Anton Bilchik; Bjoern Bruecher; Mladjan Protic; Aviram Nissan; Mina Izadjoo; Xichen Zhang; Anahid Jewett
Journal:  J Cancer       Date:  2013-01-05       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.